David Sinclair· PhD
He is now COO at Life Biosciences where he is bringing the first ever partial epigenetic reprogramming therapy to human clinical trials - a major milestone for the longevity industry.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
He is now COO at Life Biosciences where he is bringing the first ever partial epigenetic reprogramming therapy to human clinical trials - a major milestone for the longevity industry.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
And later this year, Life Biosciences expects to file an FDA application for the first human trial
Fingers crossed for the world's first epigenetic reprogramming human trial @lifebiosciences to be successful🤞https://t.co/X2B6pPgV8I https://t.co/accz5FmcSa
Honored to be on @Nasdaq’s Tower celebrating our fully subscribed $80M Series D financing supporting our Phase 1 clinical trial & Partial Epigenetic Reprogramming platform.
as we prepare to advance the first ever epigenetic reprogramming drug candidate ER-100 into the clinic this year